Search Results
You are looking at 1 - 2 of 2 items for :
- Author: Elena Navarro-González x
- Thyroid cancer - clinical x
Search for other papers by Ana Piñar-Gutiérrez in
Google Scholar
PubMed
Search for other papers by Ana R Romero-Lluch in
Google Scholar
PubMed
Search for other papers by Suset Dueñas-Disotuar in
Google Scholar
PubMed
Search for other papers by Irene de Lara-Rodríguez in
Google Scholar
PubMed
Search for other papers by María Ángeles Gálvez-Moreno in
Google Scholar
PubMed
Search for other papers by Tomás Martín-Hernández in
Google Scholar
PubMed
Search for other papers by Jorge García-Alemán in
Google Scholar
PubMed
Search for other papers by Guillermo Martínez-de Pinillos in
Google Scholar
PubMed
Search for other papers by Elena Navarro-González in
Google Scholar
PubMed
Objective
The aim of this study is to describe the characteristics, survival and prognostic factors of a cohort of patients with bone metastases (BMs) from differentiated thyroid carcinoma (DTC).
Methods
This was a multicenter retrospective observational study including patients diagnosed with BMs from DTC between 1980 and 2021. A Cox regression was performed to study prognostic factors for 5- and 10-year survival. Kaplan–Meier and log-rank tests were performed for the survival analysis and comparison between groups.
Results
Sixty-three patients were evaluated. Median follow-up from BM diagnosis was 35 (15–68) months. About 30 (48.4%) patients presented with synchronous BMs. Regarding histology, 38 (60.3%) had the papillary variant. BMs were multiple in 32 (50.8%) patients. The most frequent location was the spine (60.3%). Other metastases were present in 77.8%, mainly pulmonary (69.8%). Concerning treatment, 54 (85.9%) patients received I131, with BM uptake in 31 (49.2%) and 25 (39.7%) received treatment with multikinase inhibitors. Regarding complications, 34 (54%) patients had skeletal-related events, 34 (54%) died and 5- and 10-year overall survival was 42.4% and 20.4%, respectively. Significant prognostic factors in the multivariate analysis were the presence of lymph node involvement (hazard ratio (HR): 2.916; 95% confidence interval (CI): 1.013–8.391; P = 0.047) and treatment with I131 (HR 0.214 (95% CI 0.069–0.665); P = 0.008) at 5 years, the presence of other metastases (HR 6.844. 95% CI 1.017–46.05; P = 0.048) and treatment with I131 (HR 0.23 (95% CI 0.058–0.913); P = 0.037) at 10 years.
Conclusions
Our study reflects the management of patients with bone metastases from differentiated thyroid carcinoma in real clinical practice in several centers in southern Spain. Overall survival at 5 and 10 years was lower in patients who were not treated with I131, had nodal involvement and/or had other metastases.
Search for other papers by Juan Antonio Vallejo Casas in
Google Scholar
PubMed
Search for other papers by Marcel Sambo in
Google Scholar
PubMed
Search for other papers by Carlos López López in
Google Scholar
PubMed
Search for other papers by Manuel Durán-Poveda in
Google Scholar
PubMed
Search for other papers by Julio Rodríguez-Villanueva García in
Google Scholar
PubMed
Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Search for other papers by Marta Llanos in
Google Scholar
PubMed
Search for other papers by Elena Navarro-González in
Google Scholar
PubMed
Search for other papers by Javier Aller in
Google Scholar
PubMed
Search for other papers by Virginia Pubul in
Google Scholar
PubMed
Search for other papers by Sonsoles Guadalix in
Google Scholar
PubMed
Search for other papers by Guillermo Crespo in
Google Scholar
PubMed
Search for other papers by Cintia González in
Google Scholar
PubMed
Search for other papers by Carles Zafón in
Google Scholar
PubMed
Search for other papers by Miguel Navarro in
Google Scholar
PubMed
Search for other papers by Javier Santamaría-Sandi in
Google Scholar
PubMed
Search for other papers by Ángel Segura in
Google Scholar
PubMed
Search for other papers by Pablo Gajate in
Google Scholar
PubMed
Search for other papers by Marcelino Gómez-Balaguer in
Google Scholar
PubMed
Search for other papers by Javier Valdivia in
Google Scholar
PubMed
Search for other papers by Manel Puig-Domingo in
Google Scholar
PubMed
Search for other papers by Juan Carlos Galofré in
Google Scholar
PubMed
Search for other papers by Beatriz Castelo in
Google Scholar
PubMed
Search for other papers by María José Villanueva in
Google Scholar
PubMed
Search for other papers by Iñaki Argüelles in
Google Scholar
PubMed
Search for other papers by Lorenzo Orcajo-Rincón in
Google Scholar
PubMed
Background
Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS).
Objective
The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal.
Methods
A multicentre, longitudinal, retrospective study of adult patients diagnosed with aDTC in the Iberian Peninsula was conducted between January 2007 and December 2012. Analyses of baseline characteristics and results of initial treatments, relapse- or progression-free survival ((RP)FS) from first DTC diagnosis, OS, and prognostic factors impacting the evolution of advanced disease were evaluated.
Results
Two hundred and thirteen patients (median age: 63 years; 57% female) were eligible from 23 hospitals. Advanced disease presented at first diagnosis (de novo aDTC) included 54% of patients, while 46% had relapsed from early disease (recurrent/progressive eDTC). At initial stage, most patients received surgery (98%) and/or radioiodine (RAI) (89%), with no differences seen between median OS (95% CI) (10.4 (7.3–15.3) years) and median disease-specific-survival (95% CI) (11.1 (8.7–16.2) years; log-rank test P = 0.4737). Age at diagnosis being <55 years was associated with a lower risk of death (Wald chi-square (Wc-s) P < 0.0001), while a poor response to RAI to a higher risk of death ((Wc-s) P < 0.05). In the eDTC cohort, median (RP)FS (95% CI) was of 1.7 (1.0–2.0) years after RAI, with R0/R1 surgeries being the only common significant favourable factor for longer (RP)FS and time to aDTC ((Wc-s) P < 0.05).
Conclusion
Identification of early treatment-dependent prognostic factors for an unfavourable course of advanced disease is possible. An intensified therapeutic attitude may reverse this trend and should be considered in poor-performing patients. Prospective studies are required to confirm these findings.